Skip to main content
. 2024 Mar 25;43:90. doi: 10.1186/s13046-024-03016-9

Fig. 11.

Fig. 11

Schematic diagram of ropivacaine inhibiting the CSC-like traits of breast cancer cells. Ropivacaine targets AKT1 protein and inhibits its kinase activity, thereby blocking the NF-κB/GGT1 positive feedback loop and ultimately suppressing the CSC-like traits of breast cancer cells